Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-07

Study Completion Date

2020-06-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the study is to characterize the effect of Prolia® (denosumab) on indices of bone strength in type 2 diabetes (T2D). The investigational plan involves administration of Prolia® or identical placebo for 12 months as a randomized double-blind placebo-controlled trial in 66 T2D postmenopausal women assigned to Prolia® or placebo. The study will include assessment of different measures of bone quality: skeletal microarchitecture, including measurement of skeletal cortical pores; bone mineral density; bone material quality, and accumulation of advanced glycation endproducts (AGEs) in collagen. This information will help to determine whether Prolia® treatment in type 2 diabetes has skeletal benefits.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes

NCT07063797

Type 2 Diabetes Osteoporosis Fractures

NOT_YET_RECRUITING NA

Preventing Osteoporosis Using Denosumab

NCT02753283

Osteoporosis, Postmenopausal Osteoporosis Osteoporotic Fractures

COMPLETED PHASE4

Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP

NCT02049866

Adult Idiopathic Generalized Osteoporosis

COMPLETED PHASE2

Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®

NCT06504966

Osteoporosis

WITHDRAWN PHASE3

Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

NCT02732210

Osteoporosis, Age-Related

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type 2 Diabetes Mellitus (T2DM) has become one of the most important diseases of our time. Recent research shows that diabetes has negative effects on bones and that people with diabetes might be more likely to break a bone. We don't know the reasons for this, but we suspect that normal bone replacement is slowed down in diabetes and this could slow down the growth of new bone. It is possible that the normal bone material becomes weaker because sugar-related components ("Advanced Glycation Endproducts") are making the bone more brittle. The investigators have shown in past research that people who have type 2 diabetes are more likely to have both weaker bone with lower "bone material strength" and also higher levels of sugar-related components ("Advanced Glycation Endproducts"). This study will focus on attempting to lower the sugar-related components ("Advanced Glycation Endproducts") by treating a group of patients with type 2 diabetes with a medication Prolia® or denosumab for one year. The investigators will compare postmenopausal women both before and after denosumab use and study them in terms of different bone features based on blood tests, bone imaging, a bone indentation test and a measurement of sugar-related components in the skin. This study will help to clarify if using this medication helps improve bone strength in women with diabetes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2 Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study is a 12 month randomized (2:1 assignment) double-blind placebo-controlled trial of T2D postmenopausal women assigned to either Denosumab 60 mg subcutaneously (SC) at baseline and 6 months (n=44) or placebo (n=22); total study n=66.

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Clinical Research Coordinators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

Denosumab 60 mg/ml \[Prolia\] SC at baseline and 6 months.

Group Type EXPERIMENTAL

Denosumab 60 mg/ml [Prolia]

Intervention Type DRUG

Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits

Control Group

Placebo SC at Baseline and 6 months.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Denosumab 60 mg/ml [Prolia]

Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits

Intervention Type DRUG

Placebo

Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prolia®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. An understanding, ability and willingness to fully comply with study procedures and restrictions.
2. Ability to voluntarily provide written, signed and dated informed consent as applicable to participate in the study.
3. Postmenopausal women age ≥ 50 and ≤ 90 years at time of consent.
4. Diagnosis of T2D for ≥ 2 years. Upon review of patient's medical history, patient will be confirmed to currently have reasonably controlled T2D as assessed by the investigator, with HbA1c ≤ 8.4%. If HbA1c is ≥ 8.5%, re-screening will be allowed after approximately 3 months following adjustment of diabetes therapy.
5. DXA T-score ≤ -1.0 at one or more sites (lumbar spine, femoral neck, total hip or distal 1/3 radius).
6. Normal albumin-adjusted serum calcium level.

Exclusion Criteria

1. Hormone replacement treatment use (to avoid the influence of estrogen).
2. Fractures (excluding skull, facial bones, metacarpals, fingers, toes, and fractures associated with severe trauma) within 12 months.
3. A history of pathological fractures (eg, due to Paget's disease, myeloma, metastatic malignancy).
4. Type 1 diabetes.
5. Disorders associated with altered skeletal structure or function (chronic renal disease stage 4 or worse, chronic liver disease, malignancy, hypoparathyroidism or hyperparathyroidism, acromegaly, Cushing's syndrome, hypopituitarism, chronic obstructive pulmonary disease, alcohol intake \> 3 units/day).
6. Treatment with any of the following drugs in past year: anticonvulsant therapy, pharmacological doses of thyroid hormone (TSH\<normal is permitted if subject has normal T4, clinical euthyroidism and is in steady-state), adrenal or anabolic steroids, calcitonin, estrogen or selective estrogen receptor modulator, sodium fluoride (other than dental treatment), teriparatide, denosumab, abaloparatide, strontium or aromatase inhibitors; any history of bisphosphonate treatment. Corticosteroid use permitted if subject is in steady-state.
7. Serum 25(OH)D levels \< 20 ng/ml. If 25(OH)D levels are \< 20 ng/ml, rescreening will be allowed following a vitamin D loading regimen of 50,000 IU/week for 4 weeks. If serum 25(OH)D levels are ≥ 20 ng/ml after supplementation, the subject will be allowed to enroll.
8. Clinically significant hypersensitivity to denosumab or any components of denosumab 60 mg.
9. Known sensitivity to any of the products to be administered during the study (e.g., calcium or vitamin D).
10. Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment.
11. Female subject of child bearing potential and is not willing to use, in combination with her partner, highly effective contraception during treatment and for 5 months after the end of treatment.
12. Significant dental/oral disease, including prior history or current evidence of osteonecrosis/osteomyelitis of the jaw, or the following:

* Active dental or jaw condition which requires oral surgery
* Non-healed dental/oral surgery
* Planned invasive dental procedures for the course of the study
13. DXA T-score of ≤ -3.5 at any site.

Minimum Eligible Age

50 Years

Maximum Eligible Age

90 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No